CN1087725C
(zh)
|
1994-03-25 |
2002-07-17 |
同位素技术有限公司 |
用氘代方法增强药物效果
|
US6334997B1
(en)
|
1994-03-25 |
2002-01-01 |
Isotechnika, Inc. |
Method of using deuterated calcium channel blockers
|
AU2002224038B2
(en)
*
|
2000-11-15 |
2006-03-09 |
Banyu Pharmaceutical Co., Ltd. |
Benzimidazole derivatives
|
JP4280070B2
(ja)
|
2001-02-16 |
2009-06-17 |
コンジュケム バイオテクノロジーズ インコーポレイテッド |
胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド2(glp−2)
|
EP1369698A1
(en)
|
2002-06-07 |
2003-12-10 |
Bayer Ag |
Diagnostics and therapeutics for diseases associated with somatostatin receptor 5 (SSTR5)
|
WO2005051890A1
(en)
|
2003-11-19 |
2005-06-09 |
Smithkline Beecham Corporation |
Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
|
PL1704234T3
(pl)
|
2003-11-21 |
2012-06-29 |
Nps Pharma Inc |
Wytwarzanie glukagonopodobnego peptydu 2 i analogów
|
JP4859665B2
(ja)
|
2004-03-30 |
2012-01-25 |
武田薬品工業株式会社 |
アルコキシフェニルプロパン酸誘導体
|
JP2007284350A
(ja)
|
2004-07-27 |
2007-11-01 |
Takeda Chem Ind Ltd |
糖尿病治療剤
|
GB0420719D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
JP2008526734A
(ja)
|
2004-12-31 |
2008-07-24 |
エスケー ケミカルズ カンパニー リミテッド |
糖尿及び肥満治療予防に有効なキナゾリン誘導体
|
WO2006083612A1
(en)
|
2005-01-28 |
2006-08-10 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
AU2006210954A1
(en)
|
2005-01-31 |
2006-08-10 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
EP2295451A1
(en)
|
2005-05-04 |
2011-03-16 |
Zealand Pharma A/S |
Glucagon-like-peptide (GLP-2) analogues
|
CA2608819A1
(en)
|
2005-06-02 |
2006-12-07 |
F. Hoffmann-La Roche Ag |
Piperidin-4-yl-amide derivatives and their use as sst receptor subtype 5 antagonists
|
US20080221088A1
(en)
|
2005-06-23 |
2008-09-11 |
Vijay Kumar Potluri |
3,4-Substituted Thiazoles as Ampk Activators
|
NZ564759A
(en)
|
2005-06-30 |
2011-08-26 |
Prosidion Ltd |
GPCR agonists
|
EP1948785B1
(en)
|
2005-10-24 |
2014-01-15 |
Janssen Biotech, Inc. |
Glp-2 mimetibodies, polypeptides, compositions, methods and uses
|
US20090313709A1
(en)
|
2006-01-31 |
2009-12-17 |
Yoshihiko Kaisho |
Genetically Modified Animal and Use Thereof
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
DE602007010420D1
(de)
|
2006-04-11 |
2010-12-23 |
Arena Pharm Inc |
Verfahren zur verwendung des gpr119-rezeptors zur identifizierung von verbindungen zur erhöhung der knochenmasse bei einer person
|
TW200815377A
(en)
|
2006-04-24 |
2008-04-01 |
Astellas Pharma Inc |
Oxadiazolidinedione compound
|
EP2021327B1
(en)
|
2006-05-15 |
2012-04-04 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
FR2903695B1
(fr)
|
2006-07-13 |
2008-10-24 |
Merck Sante Soc Par Actions Si |
Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
KR100826108B1
(ko)
|
2006-08-04 |
2008-04-29 |
한국화학연구원 |
퓨란-2-카복실산 유도체 및 그의 제조 방법
|
WO2008025798A1
(en)
|
2006-08-30 |
2008-03-06 |
Biovitrum Ab (Publ) |
Pyridine compounds for treating gpr119 related disorders
|
WO2008028117A2
(en)
|
2006-08-31 |
2008-03-06 |
Centocor, Inc. |
Glp-2 mimetibodies, polypeptides, compositions, methods and uses
|
WO2008063768A2
(en)
|
2006-10-12 |
2008-05-29 |
Case Western Reserve University |
Compositions and methods for treating metabolic diseases
|
WO2008054674A2
(en)
|
2006-10-31 |
2008-05-08 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
WO2008054675A2
(en)
|
2006-10-31 |
2008-05-08 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
EA023886B1
(ru)
|
2006-11-08 |
2016-07-29 |
Зеаланд Фарма А/С |
Селективные аналоги глюкагонподобного пептида-2 (glp-2)
|
US7750048B2
(en)
|
2006-11-15 |
2010-07-06 |
Janssen Pharmaceutica Nv |
GPR40 agonists
|
AU2007325315A1
(en)
|
2006-11-28 |
2008-06-05 |
Kalypsys Inc |
Heterocyclic modulators of TGR5
|
US20090035306A1
(en)
|
2006-11-29 |
2009-02-05 |
Kalypsys, Inc. |
Quinazolinone modulators of tgr5
|
US8101634B2
(en)
|
2006-12-06 |
2012-01-24 |
Glaxosmithkline Llc |
Bicyclic compounds and use as antidiabetics
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
CA2674237C
(en)
|
2006-12-28 |
2015-11-24 |
Rigel Pharmaceuticals, Inc. |
N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
|
CA2676417C
(en)
|
2007-01-19 |
2016-06-28 |
Intercept Pharmaceuticals, Inc. |
Tgr5 modulators and methods of use thereof
|
US20080186971A1
(en)
|
2007-02-02 |
2008-08-07 |
Tarari, Inc. |
Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
|
US20080221161A1
(en)
|
2007-02-09 |
2008-09-11 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
ATE482209T1
(de)
|
2007-03-08 |
2010-10-15 |
Irm Llc |
Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität
|
JP2010526145A
(ja)
|
2007-05-04 |
2010-07-29 |
ブリストル−マイヤーズ スクイブ カンパニー |
[6,6]および[6,7]−二環式gpr119gタンパク質結合受容体アゴニスト
|
ES2388315T3
(es)
|
2007-05-04 |
2012-10-11 |
Bristol-Myers Squibb Company |
Agonistas [6,5]-bicíclicos de receptores GPR119 acoplados a la proteína G
|
KR20080099174A
(ko)
|
2007-05-07 |
2008-11-12 |
주식회사 머젠스 |
비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 나프토퀴논계 약제조성물
|
AU2008276055B2
(en)
|
2007-07-17 |
2013-01-31 |
Bristol-Myers Squibb Company |
Pyridone GPR119 G protein-coupled receptor agonists
|
US20090105124A1
(en)
|
2007-08-23 |
2009-04-23 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
NZ584049A
(en)
|
2007-09-21 |
2011-05-27 |
Sanofi Aventis |
(carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
|
RU2010115747A
(ru)
|
2007-09-21 |
2011-10-27 |
Санофи-Авентис (Fr) |
(циклопропилфенил)фенилоксаламиды, способ их получения и их применения в качестве лекарственного средства
|
ES2401233T3
(es)
|
2007-10-17 |
2013-04-18 |
Universidad de Córdoba |
Isoformas del receptor tipo 5 de somatostatina humana producidas por tratamiento alternativo y pares de oligonucleótidos para la detección de las mismas por PCR
|
JP2011016722A
(ja)
|
2007-10-23 |
2011-01-27 |
Astellas Pharma Inc |
チアゾリジンジオン化合物
|
TW200932219A
(en)
|
2007-10-24 |
2009-08-01 |
Astellas Pharma Inc |
Oxadiazolidinedione compound
|
US8304547B2
(en)
|
2007-10-24 |
2012-11-06 |
Astellas Pharma Inc. |
Azolecarboxamide compound or salt thereof
|
BRPI0818687A2
(pt)
|
2007-10-26 |
2017-05-02 |
Japan Tobacco Inc |
composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença.
|
CA2703217A1
(en)
|
2007-10-29 |
2009-05-07 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
JP5650540B2
(ja)
|
2007-12-12 |
2015-01-07 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物
|
CA2716330A1
(en)
|
2008-02-22 |
2009-08-27 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
CA2714703A1
(en)
|
2008-02-22 |
2009-08-27 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
CN102007100A
(zh)
|
2008-02-22 |
2011-04-06 |
Irm责任有限公司 |
作为gpr119活性调控剂的化合物和组合物
|
WO2009106561A1
(en)
|
2008-02-27 |
2009-09-03 |
Biovitrum Ab (Publ) |
Pyrazine compounds for treating gpr119 related disorders
|
WO2009106565A1
(en)
|
2008-02-27 |
2009-09-03 |
Biovitrum Ab (Publ) |
Agonists of gpr119
|
WO2009117421A2
(en)
|
2008-03-17 |
2009-09-24 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
KR20100134659A
(ko)
|
2008-03-31 |
2010-12-23 |
메타볼렉스, 인코포레이티드 |
옥시메틸렌 아릴 화합물 및 그것의 사용
|
EP2271619A1
(en)
|
2008-04-07 |
2011-01-12 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
KR101630466B1
(ko)
|
2008-04-11 |
2016-06-14 |
메르크 파텐트 게엠베하 |
Amp-활성화 단백질 키나아제(ampk) 활성화제로서의 티에노피리돈 유도체
|
WO2009132136A1
(en)
|
2008-04-23 |
2009-10-29 |
Rigel Pharmaceuticals, Inc. |
Carboxamide compounds for the treatment of metabolic disorders
|
SI2280952T1
(sl)
|
2008-05-05 |
2012-09-28 |
Merck Patent Gmbh |
Derivati tienopiridona kot aktivatorji AMP-aktivirane protein kinaze (AMPK)
|
AU2009249237A1
(en)
|
2008-05-19 |
2009-11-26 |
Schering Corporation |
Bicyclic heterocycle derivatives and use thereof as GPR119 modulators
|
US8188098B2
(en)
|
2008-05-19 |
2012-05-29 |
Hoffmann-La Roche Inc. |
GPR119 receptor agonists
|
CA2728018C
(en)
|
2008-06-16 |
2016-10-11 |
Merck Patent Gmbh |
Quinoxalinedione derivatives
|
KR20110026481A
(ko)
|
2008-06-20 |
2011-03-15 |
메타볼렉스, 인코포레이티드 |
아릴 gpr119 작동약 및 이의 용도
|
US8215922B2
(en)
|
2008-06-24 |
2012-07-10 |
Aurora Sfc Systems, Inc. |
Compressible fluid pumping system for dynamically compensating compressible fluids over large pressure ranges
|
MX2011000392A
(es)
|
2008-07-11 |
2011-03-01 |
Irm Llc |
4-fenoxi-metil-piperidinas como moduladoras de la actividad de gpr119.
|
TW201006821A
(en)
|
2008-07-16 |
2010-02-16 |
Bristol Myers Squibb Co |
Pyridone and pyridazone analogues as GPR119 modulators
|
WO2010014739A2
(en)
|
2008-07-29 |
2010-02-04 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
WO2010014836A2
(en)
|
2008-07-30 |
2010-02-04 |
Intercept Pharmaceuticals, Inc. |
Tgr5 modulators and methods of use thereof
|
JPWO2010013849A1
(ja)
|
2008-08-01 |
2012-01-12 |
日本ケミファ株式会社 |
Gpr119作動薬
|
WO2010016846A1
(en)
|
2008-08-08 |
2010-02-11 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
EP2337585A1
(en)
|
2008-09-19 |
2011-06-29 |
Nektar Therapeutics |
Polymer conjugates of glp-2-like peptides
|
EP3924343A1
(en)
|
2008-09-26 |
2021-12-22 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
WO2010048149A2
(en)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
WO2010047982A1
(en)
*
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
WO2010051176A1
(en)
|
2008-10-29 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
AU2009309037A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
CA2743489A1
(en)
|
2008-11-17 |
2010-05-20 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic amines for the treatment of diabetes
|
CN106380502A
(zh)
|
2008-11-19 |
2017-02-08 |
英特塞普特医药品公司 |
G蛋白偶联受体5(tgr5)调节剂及其使用方法
|
EP2376519B1
(en)
|
2008-11-19 |
2013-11-13 |
Intercept Pharmaceuticals, Inc. |
Tgr5 modulators and method of use thereof
|
AU2009326965A1
(en)
|
2008-12-12 |
2011-06-23 |
Poxel |
Tetrahydrotriazine compounds for treating diseases associated with AMPK activity
|
JP2012515782A
(ja)
|
2009-01-23 |
2012-07-12 |
シェーリング コーポレイション |
抗糖尿病性架橋および縮合化合物
|
AU2010206786A1
(en)
|
2009-01-23 |
2011-07-28 |
Merck Sharp & Dohme Corp. |
Bridged and fused heterocyclic antidiabetic compounds
|
AU2010206783A1
(en)
|
2009-01-23 |
2011-07-28 |
Merck Sharp & Dohme Corp. |
Pentafluorosulpholane-containing antidiabetic compounds
|
AR075051A1
(es)
|
2009-02-05 |
2011-03-02 |
Schering Corp |
Compuestos antidiabeticos que contienen ftalazina
|
JP2012517479A
(ja)
|
2009-02-12 |
2012-08-02 |
エグゼリクシス, インコーポレイテッド |
糖尿病および肥満の処置においてtgr5アゴニストとして使用するためのトリアゾールおよびイミダゾール誘導体
|
EP2423176A4
(en)
|
2009-04-22 |
2012-11-07 |
Astellas Pharma Inc |
CARBOXYLIC ACID COMPOUND
|
JP2012136438A
(ja)
|
2009-04-22 |
2012-07-19 |
Astellas Pharma Inc |
テトラゾール化合物
|
EP2427448A1
(en)
|
2009-05-08 |
2012-03-14 |
Pfizer Inc. |
Gpr 119 modulators
|
WO2010143733A1
(en)
|
2009-06-09 |
2010-12-16 |
Takeda Pharmaceutical Company Limited |
Novel fused cyclic compound and use thereof
|
AR077638A1
(es)
|
2009-07-15 |
2011-09-14 |
Lilly Co Eli |
Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad
|
WO2011025006A1
(ja)
|
2009-08-31 |
2011-03-03 |
日本ケミファ株式会社 |
Gpr119作動薬
|
GB0915892D0
(en)
|
2009-09-10 |
2009-10-14 |
Smithkline Beecham Corp |
Compounds
|
WO2011030139A1
(en)
|
2009-09-11 |
2011-03-17 |
Astrazeneca Ab |
4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
|
WO2011032320A1
(en)
|
2009-09-21 |
2011-03-24 |
F. Hoffmann-La Roche Ag |
Novel alkene oxindole derivatives
|
US8410127B2
(en)
|
2009-10-01 |
2013-04-02 |
Metabolex, Inc. |
Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
|
WO2011044001A1
(en)
|
2009-10-09 |
2011-04-14 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
AR078522A1
(es)
|
2009-10-15 |
2011-11-16 |
Lilly Co Eli |
Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
|
EP2314616A1
(en)
|
2009-10-23 |
2011-04-27 |
Ferring B.V. |
Peptidic GLP-2 agonists
|
CA2779398A1
(en)
|
2009-10-30 |
2011-05-05 |
Mochida Phamaceutical Co., Ltd. |
Novel 3-hydroxy-5-arylisoxazole derivative
|
EP2504342A1
(en)
|
2009-11-23 |
2012-10-03 |
Pfizer Inc. |
Imidazo-pyrazoles as gpr119 inhibitors
|
AR078948A1
(es)
|
2009-11-30 |
2011-12-14 |
Lilly Co Eli |
Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
|
WO2011069298A1
(en)
|
2009-12-11 |
2011-06-16 |
F. Hoffmann-La Roche Ag |
Novel cyclopropane indolinone derivatives
|
CN102781922A
(zh)
|
2009-12-11 |
2012-11-14 |
埃克塞利希斯股份有限公司 |
Tgr5激动剂
|
CN102712610B
(zh)
|
2009-12-25 |
2015-03-04 |
持田制药株式会社 |
新的3-羟基-5-芳基异噻唑衍生物
|
EA020588B1
(ru)
|
2009-12-29 |
2014-12-30 |
Поксел |
ТИЕНО[2,3-b]ПИРИДИНДИОНОВЫЕ АКТИВАТОРЫ АМФК И ИХ ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
|
CA2786314A1
(en)
|
2010-02-25 |
2011-09-01 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
US20130109703A1
(en)
|
2010-03-18 |
2013-05-02 |
Boehringer Ingelheim International Gmbh |
Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
|
MX2012011460A
(es)
|
2010-04-08 |
2012-11-23 |
Squibb Bristol Myers Co |
Analogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119.
|
US8344137B2
(en)
|
2010-04-14 |
2013-01-01 |
Hoffman-La Roche Inc. |
3,3-dimethyl tetrahydroquinoline derivatives
|
WO2011138307A1
(en)
|
2010-05-05 |
2011-11-10 |
Glaxosmithkline Llc |
Pyrrolo [3, 2 -d] pyrimidin-3 -yl derivatives used as activators of ampk
|
EA201270778A1
(ru)
|
2010-05-06 |
2013-04-30 |
Бристол-Майерс Сквибб Компани |
Бициклические гетероарильные аналоги в качестве модуляторов рецептора gpr119
|
EP2566862B1
(en)
|
2010-05-06 |
2015-09-16 |
Bristol-Myers Squibb Company |
Benzofuranyl analogues as gpr119 modulators
|
JP5794297B2
(ja)
|
2010-05-07 |
2015-10-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Gpr119アゴニストとしてのピリダジノン
|
AU2011256455A1
(en)
|
2010-05-17 |
2013-01-10 |
Array Biopharma Inc. |
Piperidinyl-substituted lactams as GPR119 modulators
|
AU2011256444B2
(en)
|
2010-05-18 |
2014-07-10 |
Merck Sharp & Dohme Corp. |
Spiro isoxazoline compounds as SSTR5 antagonists
|
TW201209054A
(en)
|
2010-05-28 |
2012-03-01 |
Prosidion Ltd |
Novel compounds
|
WO2011150067A1
(en)
|
2010-05-28 |
2011-12-01 |
Glaxosmithkline Llc |
Treatment of blood lipid abnormalities and other conditions
|
WO2011153435A1
(en)
|
2010-06-04 |
2011-12-08 |
Metabolex, Inc. |
Preparation of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
CN103037843A
(zh)
|
2010-06-23 |
2013-04-10 |
麦它波莱克斯股份有限公司 |
5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
|
US8592594B2
(en)
|
2010-07-02 |
2013-11-26 |
Hoffmann-La Roche Inc. |
Tetrahydro-quinoline derivatives
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
WO2012011125A1
(en)
|
2010-07-23 |
2012-01-26 |
Connexios Life Sciences Pvt. Ltd. |
Agonists of gpr40
|
ES2823350T3
(es)
|
2010-07-29 |
2021-05-06 |
Rigel Pharmaceuticals Inc |
Compuestos heterocíclicos que activan AMPK y métodos de uso de los mismos
|
EP2605658B1
(en)
|
2010-08-18 |
2016-03-23 |
Merck Sharp & Dohme Corp. |
Spiroxazolidinone compounds
|
WO2012025811A1
(en)
|
2010-08-23 |
2012-03-01 |
Lupin Limited |
Indolylpyrimidines as modulators of gpr119
|
US20120053180A1
(en)
|
2010-08-27 |
2012-03-01 |
Chemizon, A Division Of Optomagic Co., Ltd. |
Cyclohexane analogues as gpr119 agonists
|
JP5908478B2
(ja)
|
2010-08-30 |
2016-04-26 |
エヌピーエス ファーマシューティカルズ インコーポレイテッドNps Pharmaceuticals, Inc. |
h「Gly2」GLP−2の固相合成
|
JP5641663B2
(ja)
|
2010-09-10 |
2014-12-17 |
塩野義製薬株式会社 |
Ampk活性化作用を有するヘテロ環縮合イミダゾール誘導体
|
CA2811525A1
(en)
|
2010-09-17 |
2012-03-22 |
Array Biopharma Inc. |
Piperidinyl-substituted lactams as gpr119 modulators
|
ES2551183T3
(es)
|
2010-10-08 |
2015-11-16 |
Cadila Healthcare Limited |
Nuevos agonistas de GPR 119
|
JP2014001144A
(ja)
|
2010-10-08 |
2014-01-09 |
Nippon Chemiphar Co Ltd |
Gpr119作動薬
|
US9040525B2
(en)
|
2010-10-08 |
2015-05-26 |
Mochida Pharmaceutical Co., Ltd. |
Cyclic amide derivative
|
DK2646425T3
(en)
|
2010-12-01 |
2015-08-24 |
Boehringer Ingelheim Int |
Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome.
|
WO2012077655A1
(ja)
|
2010-12-07 |
2012-06-14 |
塩野義製薬株式会社 |
Gpr119アゴニスト活性を有するスピロ誘導体
|
WO2012082947A1
(en)
|
2010-12-16 |
2012-06-21 |
Irm Llc |
Compounds and compositions as tgr5 agonists
|
UY33805A
(es)
|
2010-12-17 |
2012-07-31 |
Boehringer Ingelheim Int |
?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?.
|
KR20140003496A
(ko)
|
2011-01-21 |
2014-01-09 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병, 비만 및 관련 질환들을 치료하기 위한, gpr119 조절제로서의 융합된 디하이드로푸란
|
US8809369B2
(en)
|
2011-01-26 |
2014-08-19 |
Hoffmann-La Roche Inc. |
Tetrahydroquinoline derivatives
|
CN102617548A
(zh)
|
2011-01-31 |
2012-08-01 |
北京赛林泰医药技术有限公司 |
作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用
|
SG192645A1
(en)
|
2011-02-17 |
2013-09-30 |
Takeda Pharmaceutical |
Production method of optically active dihydrobenzofuran derivative
|
MY159058A
(en)
*
|
2011-02-25 |
2016-12-15 |
Merck Sharp & Dohme |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
|
JP2014094886A
(ja)
|
2011-02-28 |
2014-05-22 |
Nippon Chemiphar Co Ltd |
Gpr119作動薬
|
WO2012119978A1
(en)
|
2011-03-07 |
2012-09-13 |
Glaxosmithkline Llc |
Quinolinone derivatives
|
US20130345243A1
(en)
|
2011-03-07 |
2013-12-26 |
Glaxosmithkline Llc |
1h-pyrollo[3,2-d]pyrimidinedione derivatives
|
WO2012138919A2
(en)
|
2011-04-08 |
2012-10-11 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
|
WO2012145361A1
(en)
|
2011-04-19 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2012145603A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
US20140051714A1
(en)
|
2011-04-22 |
2014-02-20 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
NZ617409A
(en)
|
2011-04-27 |
2015-08-28 |
Mochida Pharm Co Ltd |
Novel 3-hydroxyisothiazole 1-oxide derivative
|
CN103619817A
(zh)
|
2011-04-28 |
2014-03-05 |
百时美施贵宝公司 |
新颖的二环含氮杂芳基tgr5受体调节剂
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2013054338A1
(en)
|
2011-07-06 |
2013-04-18 |
Cadila Healthcare Limited |
2-thio-imidazole derivatives as tgr5 modulators
|
US9567330B2
(en)
|
2011-07-15 |
2017-02-14 |
Shionogi & Co., Ltd. |
Azabenzimidazole derivative having AMPK-activating activity
|
TWI537262B
(zh)
|
2011-08-17 |
2016-06-11 |
美國禮來大藥廠 |
供治療糖尿病使用之新穎1,2,3,4-四氫喹啉衍生物
|
BR112014005744B1
(pt)
|
2011-09-12 |
2020-11-17 |
Amunix Operating Inc. |
proteína de fusão recombinante, composição farmacêutica compreendendo a referida proteína e uso da mesma referência cruzada com pedido relacionado
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2013057743A1
(en)
|
2011-10-21 |
2013-04-25 |
Connexios Life Sciences Pvt. Ltd |
Process for the preparation of an aryl oxime and salts thereof
|
US20140256756A1
(en)
|
2011-11-03 |
2014-09-11 |
Array Biopharma Inc. |
Piperidinyl-substituted lactams as gpr119 modulators
|
WO2013074388A1
(en)
|
2011-11-15 |
2013-05-23 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds useful as gpr119 agonists
|
IN2014MN01433A
(es)
|
2011-12-21 |
2015-07-03 |
Ardelyx Inc |
|
CN103429581B
(zh)
|
2012-01-12 |
2015-08-26 |
江苏恒瑞医药股份有限公司 |
多环类衍生物、其制备方法及其在医药上的应用
|
JP6121339B2
(ja)
|
2012-02-13 |
2017-04-26 |
武田薬品工業株式会社 |
芳香環化合物
|
US9382188B2
(en)
|
2012-02-13 |
2016-07-05 |
Takeda Pharmaceutical Company Limited |
Aromatic ring compound
|
WO2013122821A1
(en)
|
2012-02-14 |
2013-08-22 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds useful as gpr119 agonists
|
WO2013128378A1
(en)
|
2012-02-28 |
2013-09-06 |
Piramal Enterprises Limited |
Phenyl alkanoic acid derivatives as gpr agonists
|
US8642585B2
(en)
|
2012-03-26 |
2014-02-04 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
US8889730B2
(en)
|
2012-04-10 |
2014-11-18 |
Pfizer Inc. |
Indole and indazole compounds that activate AMPK
|
WO2013154163A1
(ja)
|
2012-04-11 |
2013-10-17 |
持田製薬株式会社 |
新規5-アリール-1,2-チアジナン誘導体
|
US8809376B2
(en)
|
2012-04-30 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
AU2013255752B2
(en)
|
2012-05-03 |
2017-11-09 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (GLP-2) analogues
|
WO2013167514A1
(en)
|
2012-05-07 |
2013-11-14 |
Boehringer Ingelheim International Gmbh |
New 2,3-dihydro-furo[2,3-c]pyridines, their use as modulators of the g-protein-coupled receptor gpr119 and pharmaceutical compositions comprising them
|
WO2013173198A1
(en)
|
2012-05-16 |
2013-11-21 |
Bristol-Myers Squibb Company |
Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
|
US8633182B2
(en)
|
2012-05-30 |
2014-01-21 |
Boehringer Ingelheim International Gmbh |
Indanyloxyphenylcyclopropanecarboxylic acids
|
EP2679591A1
(en)
|
2012-06-29 |
2014-01-01 |
Poxel |
Thienopyridone derivatives useful as activators of AMPK
|
WO2014019186A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
EP2888006B1
(en)
|
2012-08-22 |
2019-04-24 |
Merck Sharp & Dohme Corp. |
Novel azabenzimidazole tetrahydropyran derivatives useful as ampk activators
|
EP2887807B1
(en)
|
2012-08-22 |
2019-09-18 |
Merck Sharp & Dohme Corp. |
Benzimidazole hexahydrofuro[3,2-b]furan derivatives useful as amp-activated protein kinase activators
|
WO2014031441A1
(en)
|
2012-08-22 |
2014-02-27 |
Merck Sharp & Dohme Corp. |
Novel benzimidazole tetrahydrofuran derivatives
|
US9290517B2
(en)
|
2012-08-22 |
2016-03-22 |
Merck Sharp & Dohme Corp. |
Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives
|
US9527839B2
(en)
|
2012-08-22 |
2016-12-27 |
Merck Sharp & Dohme Corp. |
Benzimidazole tetrahydropyran derivatives
|
EP2888008B1
(en)
|
2012-08-22 |
2018-12-26 |
Merck Sharp & Dohme Corp. |
Novel azabenzimidazole tetrahydrofuran derivatives
|
WO2014052619A1
(en)
|
2012-09-27 |
2014-04-03 |
Irm Llc |
Piperidine derivatives and compositions as modulators of gpr119 activity
|
AR092924A1
(es)
|
2012-10-09 |
2015-05-06 |
Sanofi Sa |
Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
|
US9777038B2
(en)
|
2012-10-26 |
2017-10-03 |
Intercept Pharmaceuticals, Inc. |
Process for preparing bile acid derivatives
|
WO2014069426A1
(ja)
|
2012-10-31 |
2014-05-08 |
塩野義製薬株式会社 |
Ampk活性化作用を有するベンズイミダゾールおよびアザベンズイミダゾール誘導体
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
TWI692469B
(zh)
|
2012-11-09 |
2020-05-01 |
南韓商Lg化學股份有限公司 |
Gpr40受體促效劑,製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
|
KR20150088878A
(ko)
|
2012-11-28 |
2015-08-03 |
베링거 인겔하임 인터내셔날 게엠베하 |
신규한 인다닐옥시디하이드로벤조푸라닐아세트산
|
RU2693382C2
(ru)
|
2012-11-28 |
2019-07-02 |
Интерсепт Фармасьютикалз, Инк. |
Лечение заболевания дыхательной системы
|
JP6283862B2
(ja)
|
2012-12-07 |
2018-02-28 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規インダニルオキシジヒドロベンゾフラニル酢酸
|
WO2014100021A1
(en)
|
2012-12-17 |
2014-06-26 |
Exelixis, Inc. |
Tgr5 agonists: imidazole and triazole compounds containing a quaternary nitrogen
|
WO2014100025A1
(en)
|
2012-12-17 |
2014-06-26 |
Exelixis, Inc. |
Tgr5 agonists having an imidazole or triazole core with subtituent having a quaternary nitrogen
|
WO2014096440A2
(en)
|
2012-12-21 |
2014-06-26 |
Novozymes Biopharma Dk A/S |
Composition
|
WO2014122067A1
(en)
|
2013-02-06 |
2014-08-14 |
Boehringer Ingelheim International Gmbh |
New indanyloxydihydrobenzofuranylacetic acids
|
EP2769974A1
(en)
|
2013-02-21 |
2014-08-27 |
Debiopharm S.A. |
Novel AMPK activator
|
US9840512B2
(en)
|
2013-02-22 |
2017-12-12 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US9890119B2
(en)
|
2013-02-27 |
2018-02-13 |
Shionogi & Co., Ltd. |
Indole and azaindole derivative having AMPK-activating activity
|
CN104059039B
(zh)
|
2013-03-22 |
2017-03-15 |
正大天晴药业集团股份有限公司 |
具有gpr40受体功能调节作用的稠环化合物
|
CN104109115B
(zh)
|
2013-04-16 |
2016-11-23 |
中国科学院上海药物研究所 |
一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途
|
WO2014170842A2
(en)
|
2013-04-17 |
2014-10-23 |
Piramal Enterprises Limited |
Substituted alkyl carboxylic acid derivatives as gpr agonists
|
JP6372891B2
(ja)
|
2013-04-24 |
2018-08-15 |
塩野義製薬株式会社 |
Ampk活性化作用を有する5−オキシベンズイミダゾールおよび5−オキシアザベンズイミダゾール誘導体
|
CN104870429B
(zh)
|
2013-05-22 |
2017-05-03 |
四川海思科制药有限公司 |
苯并呋喃衍生物、其制备方法及其在医药上的应用
|
KR20160034893A
(ko)
|
2013-06-13 |
2016-03-30 |
패스트 포워드 파머슈티컬스 비.브이. |
Cd40 시그널링 억제제 및 추가 화합물로서, 상기 추가 화합물은 담즙산, 담즙산 유도체, tgr5-수용체 아고니스트, fxr 아고니스트 또는 이들의 조합이고, 만성 염증의 치료용, 및 위장 암 또는 섬유증의 예방용인, cd40 시그널링 억제제 및 추가 화합물
|
WO2014202528A1
(en)
|
2013-06-20 |
2014-12-24 |
Boehringer Ingelheim International Gmbh |
Olefin substituted oxindoles having ampk activity
|
EP3010905A1
(en)
|
2013-06-20 |
2016-04-27 |
Boehringer Ingelheim International GmbH |
Spiro-substituted oxindole derivatives having ampk activity
|
WO2015000412A1
(zh)
|
2013-07-02 |
2015-01-08 |
四川海思科制药有限公司 |
苯并环丁烯类衍生物、其制备方法及其在医药上的应用
|
PL3022210T3
(pl)
|
2013-07-17 |
2018-08-31 |
Boehringer Ingelheim International Gmbh |
Nowy pochodne azabenzimidazolu
|
CN105143181B
(zh)
|
2013-07-26 |
2017-12-26 |
四川海思科制药有限公司 |
三元并环羧酸类衍生物、其制备方法及其在医药上的应用
|
PL3027642T3
(pl)
|
2013-07-31 |
2021-01-11 |
Amgen Inc. |
Konstrukty czynnika różnicowania wzrostu 15 (GDF-15)
|
EP3031799B1
(en)
|
2013-08-09 |
2018-04-04 |
Takeda Pharmaceutical Company Limited |
Aromatic compound
|
CN104418801B
(zh)
|
2013-08-19 |
2016-10-05 |
上海润诺生物科技有限公司 |
苯并哌啶环与苯并吗啉环类化合物、其制法及医药应用
|
CN105473595A
(zh)
|
2013-08-23 |
2016-04-06 |
福建海西新药创制有限公司 |
治疗糖尿病的羧酸化合物
|
WO2015028960A1
(en)
|
2013-08-28 |
2015-03-05 |
Piramal Enterprises Limited |
Substituted heterocyclic derivatives as gpr agonists and uses thereof
|
CN105246875A
(zh)
|
2013-09-03 |
2016-01-13 |
四川海思科制药有限公司 |
茚满衍生物及其制备方法和在医药上的应用
|
WO2015044073A1
(en)
|
2013-09-26 |
2015-04-02 |
Boehringer Ingelheim International Gmbh |
Process and intermediates for preparing indanyloxydihydrobenzofuranyl acetic acid derivatives as gpr40 agonists
|
JO3442B1
(ar)
|
2013-10-07 |
2019-10-20 |
Takeda Pharmaceuticals Co |
مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
EP3063148B1
(en)
|
2013-10-31 |
2020-04-29 |
Boehringer Ingelheim International GmbH |
Azabenzimidazole derivatives
|
WO2015062486A1
(en)
|
2013-10-31 |
2015-05-07 |
Sunshine Lake Pharma Co., Ltd. |
Biphenyl compounds and uses thereof
|
EA201690888A1
(ru)
|
2013-11-14 |
2016-10-31 |
Кадила Хелзкэр Лимитед |
Новые гетероциклические соединения
|
ES2747973T3
(es)
|
2013-11-15 |
2020-03-12 |
Merck Sharp & Dohme |
Compuestos tricíclicos antidiabéticos
|
EP3074384B1
(en)
|
2013-11-26 |
2019-05-22 |
Chong Kun Dang Pharmaceutical Corp. |
Amide derivatives for gpr119 agonist
|
EP3074375B1
(en)
|
2013-11-28 |
2018-04-04 |
Boehringer Ingelheim International GmbH |
New indanyloxyphenylcyclopropanecarboxylic acids
|
US9957219B2
(en)
|
2013-12-04 |
2018-05-01 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
TW201609722A
(zh)
|
2013-12-13 |
2016-03-16 |
美國禮來大藥廠 |
新穎三唑并吡啶化合物
|
EP2886541A1
(en)
|
2013-12-19 |
2015-06-24 |
Sanofi |
Oxindole derivatives, preparation thereof and therapeutic use in the treatment of AMPK-related diseases
|
WO2015089809A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Antidiabetic substituted heteroaryl compounds
|
JP6170255B2
(ja)
|
2014-01-10 |
2017-07-26 |
イーライ リリー アンド カンパニー |
イソプロピルトリアゾロピリジン化合物
|
JP6211200B2
(ja)
|
2014-01-10 |
2017-10-11 |
イーライ リリー アンド カンパニー |
フェニル−トリアゾロ−ピリジン化合物
|
EP3102198B1
(en)
|
2014-02-06 |
2020-08-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic compounds
|
AR099936A1
(es)
|
2014-04-04 |
2016-08-31 |
Sanofi Sa |
Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
|
TW201623286A
(zh)
|
2014-04-04 |
2016-07-01 |
賽諾菲公司 |
作為gpr119調控劑用於治療糖尿病、肥胖、血脂異常及相關病症之異吲哚啉酮化合物
|
CN106132949A
(zh)
|
2014-04-04 |
2016-11-16 |
赛诺菲 |
作为治疗糖尿病、肥胖、血脂障碍及相关病症的gpr119调节剂的取代的茚满酮化合物
|
WO2015160772A1
(en)
|
2014-04-15 |
2015-10-22 |
Janssen Pharmaceutica Nv |
Tetrahydro-benzoimidazolyl modulators of tgr5
|
MX2016014642A
(es)
|
2014-05-09 |
2017-05-25 |
Kineta Inc |
Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.
|
WO2015176267A1
(en)
|
2014-05-22 |
2015-11-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
US10166246B2
(en)
|
2014-05-27 |
2019-01-01 |
City Of Hope |
TGR5 agonist complexes for treating diabetes and cancer
|
MA39881B1
(fr)
|
2014-05-29 |
2020-02-28 |
Bar Pharmaceuticals S R L |
Dérivés de cholane à utiliser dans le traitement et/ou la prévention de maladies médiées par fxr et tgr5/gpbar1
|
EP3157947A1
(en)
|
2014-06-23 |
2017-04-26 |
Novartis AG |
Hsa-gdf-15 fusion polypeptide and use thereof
|
WO2016001224A1
(en)
|
2014-06-30 |
2016-01-07 |
Debiopharm International S.A. |
Novel activators of amp-activated protein kinases
|
EP3164538A1
(en)
|
2014-07-02 |
2017-05-10 |
Arçelik Anonim Sirketi |
Built-in household appliance unpowered control and status indication device
|
EP3177287B1
(en)
|
2014-08-08 |
2022-02-23 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US10662171B2
(en)
|
2014-08-08 |
2020-05-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US10100042B2
(en)
|
2014-08-08 |
2018-10-16 |
Merck Sharp & Dohme Corp. |
[5,6]—fused bicyclic antidiabetic compounds
|
WO2016019587A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
[7, 6]-fused bicyclic antidiabetic compounds
|
WO2016023789A1
(en)
|
2014-08-11 |
2016-02-18 |
Boehringer Ingelheim International Gmbh |
Azabenzimidazole derivatives as amp protein kinase agonistes
|
MX2017002275A
(es)
|
2014-08-27 |
2017-05-03 |
Shionogi & Co |
Derivado de azaindol que tiene actividad activadora de proteina cinasa activada por monofosfato de adenosina (ampk).
|
WO2016032120A1
(ko)
|
2014-08-27 |
2016-03-03 |
씨제이헬스케어 주식회사 |
신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도
|
WO2016054208A1
(en)
|
2014-10-03 |
2016-04-07 |
Mayo Foundation For Medical Education And Research |
Targeting tgr5 to treat disease
|
TW201629033A
(zh)
|
2014-10-08 |
2016-08-16 |
健生藥品公司 |
作為治療第二型糖尿病之gpr40促效劑的經取代苯并噻吩基衍生物
|
WO2016068453A1
(en)
|
2014-10-27 |
2016-05-06 |
Dong-A St Co., Ltd. |
Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
|
WO2016068099A1
(ja)
|
2014-10-28 |
2016-05-06 |
塩野義製薬株式会社 |
Ampk活性化作用を有する複素環誘導体
|
JP2017537894A
(ja)
|
2014-10-31 |
2017-12-21 |
グブラ エーピーエス |
Glp−1rおよびglp−2r二重アゴニスト活性を有する組成物及びペプチド
|
US10266560B2
(en)
|
2014-11-06 |
2019-04-23 |
Enanta Pharmaceuticals, Inc. |
Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
|
US11578097B2
(en)
|
2014-11-26 |
2023-02-14 |
Enanta Pharmaceuticals, Inc. |
Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
|
WO2016092413A1
(en)
|
2014-12-10 |
2016-06-16 |
Pfizer Inc. |
Indole and indazole compounds that activate ampk
|
JP6612880B2
(ja)
|
2015-01-16 |
2019-11-27 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Amp活性化タンパク質キナーゼのアゴニストとしての新規アザベンゾイミダゾール誘導体
|
EP3245212B1
(en)
|
2015-01-16 |
2019-03-13 |
Boehringer Ingelheim International GmbH |
New azabenzimidazole derivatives
|
RU2017130466A
(ru)
|
2015-02-11 |
2019-03-12 |
Энанта Фармасьютикалс, Инк. |
Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
|
ES2886766T3
(es)
|
2015-03-31 |
2021-12-20 |
Enanta Pharm Inc |
Derivados del ácido biliar como agonistas de FXR/TGR5 y métodos de uso de estos
|
TW201712012A
(zh)
|
2015-06-16 |
2017-04-01 |
美國禮來大藥廠 |
2-側氧基-1,3,8-三氮雜螺[4.5]癸-3-基羧酸衍生物
|
AU2016280806B2
(en)
|
2015-06-19 |
2021-01-28 |
Intercept Pharmaceuticals, Inc. |
TGR5 modulators and methods of use thereof
|
WO2017002786A1
(ja)
|
2015-07-02 |
2017-01-05 |
サントリーホールディングス株式会社 |
Glp-2分泌促進用組成物
|
US9617251B2
(en)
|
2015-08-07 |
2017-04-11 |
Boehringer Ingelheim International Gmbh |
Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
CA2994687A1
(en)
|
2015-08-07 |
2017-02-16 |
Intercept Pharmaceuticals, Inc. |
Methods for preparation of bile acids and derivatives thereof
|
WO2017027309A1
(en)
|
2015-08-12 |
2017-02-16 |
Janssen Pharmaceutica Nv |
Gpr40 agonists for the treatment of type ii diabetes
|
US9856245B2
(en)
|
2015-08-12 |
2018-01-02 |
Janssen Pharmaceutica Nv |
GPR40 agonists for the treatment of type II diabetes
|
US9908873B2
(en)
|
2015-08-12 |
2018-03-06 |
Janssen Pharmaceutica Nv |
GPR40 agonists for the treatment of type II diabetes
|
EP3347358B1
(en)
|
2015-09-09 |
2019-11-27 |
Boehringer Ingelheim International GmbH |
[{[2,3-dihydro-1h-inden-1-yl]amino}-2h,3h-furo[3,2-b]pyridin-3-yl]acetic acids, pharmaceutical compositions and uses thereof
|
EP3353189A4
(en)
|
2015-09-24 |
2019-06-19 |
Intercept Pharmaceuticals, Inc. |
METHODS AND INTERMEDIATES FOR PREPARING BILARY ACID DERIVATIVES
|
CA3004275A1
(en)
|
2015-11-06 |
2017-05-11 |
Intercept Pharmaceuticals, Inc. |
Methods for the preparation of obeticholic acid and derivatives thereof
|
WO2017106112A1
(en)
|
2015-12-16 |
2017-06-22 |
Merck Sharp & Dohme Corp. |
Methods of preventing or treating hypoglycemia by administering a gpr119 agonist
|
TWI773657B
(zh)
|
2015-12-18 |
2022-08-11 |
美商亞德利克斯公司 |
作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物
|
WO2017147137A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
|
WO2017147174A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
US10364267B2
(en)
|
2016-02-23 |
2019-07-30 |
Enanta Pharmaceuticals, Inc. |
Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
JPWO2017146186A1
(ja)
|
2016-02-26 |
2018-12-20 |
塩野義製薬株式会社 |
Ampk活性化作用を有する5−フェニルアザインドール誘導体
|
JP2019510739A
(ja)
|
2016-02-29 |
2019-04-18 |
イーライ リリー アンド カンパニー |
Gfral受容体療法
|
WO2017172505A1
(en)
|
2016-03-29 |
2017-10-05 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US10526345B2
(en)
|
2016-04-08 |
2020-01-07 |
Mankind Pharma Ltd. |
Compounds as GPR119 agonists
|
US10208030B2
(en)
|
2016-04-08 |
2019-02-19 |
Mankind Pharma Ltd. |
GPR119 agonist compounds
|
US10106553B2
(en)
|
2016-04-11 |
2018-10-23 |
Janssen Pharmaceutica Nv |
Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
|
CA3020698A1
(en)
|
2016-04-13 |
2017-10-19 |
Intercept Pharmaceuticals, Inc. |
Methods of treating or preventing hepatocellular carcinoma
|
CN109311912A
(zh)
|
2016-04-26 |
2019-02-05 |
盐野义制药株式会社 |
具有ampk活化作用的5-取代氮杂苯并咪唑衍生物
|
CN109476661A
(zh)
|
2016-05-20 |
2019-03-15 |
盐野义制药株式会社 |
具有ampk活化作用的5-取代苯并咪唑及5-取代氮杂苯并咪唑衍生物
|
WO2017222713A1
(en)
|
2016-06-24 |
2017-12-28 |
Indiana University Research & Technology Corporation |
A gpr119-based signaling system in the murine eye regulates intraocular pressure in a sex-dependent manner
|
US11236055B2
(en)
|
2016-07-01 |
2022-02-01 |
Venenum Biodesign, LLC |
Non-systemic TGR5 agonists
|
US10654834B2
(en)
|
2016-07-01 |
2020-05-19 |
Venenum Biodesign, LLC |
Non-systemic TGR5 agonists
|
WO2018009778A1
(en)
|
2016-07-07 |
2018-01-11 |
Baylor College Of Medicine |
Combination of glp-1 and glp-2 for treating or preventing metabolic diseases, disorders and syndromes
|
KR20190035752A
(ko)
|
2016-08-03 |
2019-04-03 |
사이머베이 쎄라퓨틱스, 인코퍼레이티드 |
염증성 위장 질환 또는 위장 상태를 치료하기 위한 옥시메틸렌 아릴 화합물
|
EP3500558B1
(en)
|
2016-08-19 |
2022-11-02 |
Rigel Pharmaceuticals, Inc. |
Benzimidazole direct ampk activators
|
WO2018064441A1
(en)
|
2016-09-30 |
2018-04-05 |
Intercept Pharmaceuticals, Inc |
Crystalline forms of a bile acid derivative
|
CA3038846A1
(en)
|
2016-10-12 |
2018-04-19 |
Janssen Biotech, Inc. |
Methods for screening for modulators of gdf15-like biological activity
|
WO2018081047A1
(en)
|
2016-10-25 |
2018-05-03 |
Janssen Pharmaceutica Nv |
Cyclohexyl gpr40 agonists for the treatment of type ii diabetes
|
WO2018077699A1
(en)
|
2016-10-25 |
2018-05-03 |
Boehringer Ingelheim International Gmbh |
Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
EP3544958B1
(en)
|
2016-11-28 |
2021-03-24 |
Boehringer Ingelheim International GmbH |
Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
CA3044915A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
WO2018104559A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
KR102502040B1
(ko)
|
2016-12-09 |
2023-02-24 |
질랜드 파마 에이/에스 |
아실화 glp-1/glp-2 이중 효능제
|
WO2018103868A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
WO2018104558A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
KR102007633B1
(ko)
|
2016-12-15 |
2019-08-06 |
일동제약(주) |
신규 페닐 프로피온 산 유도체 및 이의 용도
|
EP3558298A4
(en)
|
2016-12-20 |
2020-08-05 |
Merck Sharp & Dohme Corp. |
ANTIDIABETIC SPIROCHROMAN COMPOUNDS
|
EP3573953A1
(en)
|
2017-01-26 |
2019-12-04 |
Boehringer Ingelheim International GmbH |
Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
US10253004B2
(en)
|
2017-01-26 |
2019-04-09 |
Boehringer Ingelheim International Gmbh |
Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
CN110177773B
(zh)
|
2017-01-26 |
2023-08-25 |
勃林格殷格翰国际有限公司 |
苄基氨基吡啶基环丙烷羧酸、其药物组合物及其用途
|
CN110312714B
(zh)
|
2017-01-26 |
2022-12-09 |
勃林格殷格翰国际有限公司 |
苄基氧基吡嗪基环丙烷甲酸、其药物组合物和用途
|
US10793530B2
(en)
|
2017-01-26 |
2020-10-06 |
Boehringer Ingelheim International Gmbh |
Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
WO2018142363A1
(en)
|
2017-02-06 |
2018-08-09 |
Orbicular Pharmaceutical Technologies Private Limited |
Ready to use compositions of glp-2 analogues through self-administrable devices
|
US10550127B1
(en)
|
2017-02-08 |
2020-02-04 |
Boehringer Ingelheim International Gmbh |
Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
|
WO2018153849A1
(en)
|
2017-02-21 |
2018-08-30 |
Sanofi |
Azetidine compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
|
WO2018161077A1
(en)
|
2017-03-03 |
2018-09-07 |
The Regents Of The University Of California |
Methods of treating conditions associated with leaky gut barrier
|
GB201704714D0
(en)
|
2017-03-24 |
2017-05-10 |
Caldan Therapeutics Ltd |
Pharmaceutical compounds
|
WO2018181847A1
(ja)
|
2017-03-31 |
2018-10-04 |
武田薬品工業株式会社 |
芳香環化合物
|
AR111199A1
(es)
|
2017-03-31 |
2019-06-12 |
Takeda Pharmaceuticals Co |
Compuesto aromático agonista de gpr40
|
IT201700039329A1
(it)
|
2017-04-10 |
2018-10-10 |
Univ Pisa |
Derivati benzofuranici quali attivatori di ampk
|
IT201700039562A1
(it)
|
2017-04-10 |
2018-10-10 |
Univ Pisa |
Derivati isoindolinici quali attivatori di ampk
|
CN107162921B
(zh)
|
2017-05-27 |
2019-12-13 |
中国药科大学 |
一类苯氧乙酸衍生物、其制备方法及其作为药物的用途
|
WO2018222701A1
(en)
|
2017-05-30 |
2018-12-06 |
Intercept Pharmaceuticals, Inc. |
Treatment of renal diseases with a bile acid derivative
|
WO2018226724A1
(en)
|
2017-06-05 |
2018-12-13 |
Intercept Pharmaceuticals, Inc. |
Treatment and prevention of diabetic eye diseases with a bile acid derivatives
|
SG11201912161SA
(en)
|
2017-06-16 |
2020-01-30 |
Zealand Pharma As |
Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
|
IL271343B2
(en)
|
2017-06-23 |
2023-12-01 |
Intercept Pharmaceuticals Inc |
Methods and intermediates for the preparation of bile acid derivatives
|
BR112020003736A2
(pt)
|
2017-08-22 |
2020-09-08 |
Shire-Nps Pharmaceuticals, Inc. |
polipeptídeos de fusão de glp-2 e usos para tratar e prevenir condições gastrointestinais
|
WO2019086559A1
(fr)
|
2017-10-31 |
2019-05-09 |
Adocia |
Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
MX2020004620A
(es)
|
2017-11-06 |
2020-10-12 |
Shire Nps Pharmaceuticals Inc |
Analogos y pepticuerpos de peptido 2 similar a glucagon (glp-2) para administracion antes, durante o despues de cirugia.
|
EP3709995A4
(en)
|
2017-11-16 |
2021-04-14 |
Merck Sharp & Dohme Corp. |
BICYCLIC ANTIDIABETIC COMPOUNDS
|
FI3737470T3
(fi)
|
2018-01-08 |
2023-03-19 |
Celon Pharma Sa |
3-fenyyli-4-heksyylihappojohdannaisia GPR40-agonisteina
|
CN113784708A
(zh)
|
2019-05-15 |
2021-12-10 |
雀巢产品有限公司 |
菲ampk活化剂化合物、组合物、方法及其用途
|
KR20230012597A
(ko)
|
2020-05-19 |
2023-01-26 |
칼리오페, 인크. |
Ampk 활성화제
|
AU2021297323A1
(en)
|
2020-06-26 |
2023-02-16 |
Kallyope, Inc. |
AMPK activators
|
WO2023097187A1
(en)
|
2021-11-23 |
2023-06-01 |
Kallyope, Inc. |
Ampk activators
|
WO2023097189A1
(en)
|
2021-11-23 |
2023-06-01 |
Kallyope, Inc. |
Ampk activators
|
WO2023097190A1
(en)
|
2021-11-23 |
2023-06-01 |
Kallyope, Inc. |
Ampk activators
|